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ABSTRAK
Tujuan: untuk mengetahui pengaruh pemberian suplementasi nutrisi tinggi PUFA pada status inflamasi pasien 
kanker serviks stadium lanjut. Metode: uji klinis acak tersamar ganda pada pasien kanker serviks stadium lanjut 
yang sedang menjalani terapi radiasi eksterna di Departemen Radioterapi RS. Cipto Mangunkusumo, Jakarta, 
periode April 2013-April 2014. Status inflamasi dinilai dari kadar prostaglandin E2 (PGE2) serum melalui metode 
Elisa. Suplementasi nutrisi mengandung isokalori dan isoprotein, serta mengandung PUFA dengan rasio asam 
lemak (AL) n-6 : n-3 = 1,27 : 1 dan tanpa PUFA. Data dianalisis dengan Uji statistik Saphiro-Wilk, T test tidak 
berpasangan dan Mann-Whitney. Hasil: secara statistik tidak didapatkan perbedaan bermakna kadar PGE2 antara 
kelompok perlakuan dan kontrol (p = 0,127), tetapi secara klinis didapatkan perbedaan yang nyata pada kadar 
PGE2, yaitu kelompok perlakuan mengalami penurunan sebesar 8,9%, sedangkan kelompok kontrol mengalami 
kenaikan sebesar 28,1%. Kesimpulan: pemberian suplementasi nutrisi diperkaya PUFA mampu menurunkan 
status inflamasi  pada pasien kanker serviks stadium lanjut. Penurunan kadar PGE2 akan menurunkan ketahanan 
hidup sel kanker, sehingga pemberian nutrisi diperkaya PUFA dengan rasio AL n-6 : n-3 = 1,27 :1 bersamaan 
terapi radiasi dapat meningkatkan respon tumor terhadap radiasi.
Kata kunci: kanker serviks, asam lemak n-3 dan n-6 , kadar PGE2.
ABSTRACT
Aim: to identify the effect of high-PUFA dietary supplementation on inflammatory status of patients with 
advanced cervical cancer. Methods: a randomized double-blind clinical trial was conducted in patients with 
advanced cervical cancer who had undergone external radiation therapy at Department of Radiotherapy, 
Cipto Mangunkusumo Hospital, Jakarta, between April 2013 and April 2014. The inflammatory status was 
evaluated based on serum prostaglandin E2 (PGE2) levels using ELISA method. The dietary supplementation 
was isocaloric, isoprotein and contained PUFA with a ratio of ω-6: ω-3 fatty acid = 1.27:1 and supplementation 
without PUFA. Data were analyzed with statistical tests, including Shapiro-Wilk test, independent T-test 
and Mann–Whitney test. Results: there was statistically no significant difference on PGE2 level between 
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treatment and control groups (p=0.127). However, there was clinically significant difference, in which the 
treatment group had reduced PGE2 level by 8.9%; while the control group had increased level by 28.1%. 
Conclusion: dietary supplementation enriched with PUFA can reduce inflammatory status in patients with 
advanced cervical cancer. Reduced PGE2 level will lower the survival of cancer cells; therefore dietary 
supplementation enriched with PUFA with a ratio of ω-6 : ω-3 fatty acid = 1.27 : 1 along with radiation therapy 
may improve tumor response to radiation.
Key words: cervical cancer, ω-3 PUFA, ω-6 PUFA, PGE2 level.
INTRODUCTION
Approximately 75% patients with cervical 
cancer turn to hospital at advanced stage 
(>IIB stage). The five-year survival rate for 
advanced cervical cancer is about 0-40%.1 The 
main treatment for this cancer is radiation or 
chemoradiation therapy. A combined treatment 
with chemotherapy apparently does not give a 
better treatment response within the 3-month 
follow up; moreover, it even causes more severe 
side effects than radiation therapy alone.2 
Some in vivo and in vitro studies have 
provided evidences that ω-3 fatty acid (FA) 
has pro-apoptosis, anti-inflammatory, anti-
proliferative and anti-angiogenesis effects.3-5 
Biological effects of ω-3 FA is often associated 
with the competitive inhibitory effect on 
eicosanoid products produced by ω-6 FA. 
Eicosanoids derived from ω-6 FA, linoleic 
acid (LA) or arachidonic acid (AA), have 
pro-inflammatory and tumor angiogenesis 
properties; while eicosanoids originated from 
ω-3 FA, i.e. eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA), have anti-
inflammatory properties and does not stimulate 
angiogenesis.3,4 The molecular mechanism of 
anti-tumor effect of ω-3 FA has various pathways 
including the COX-2-PGE2 pathway. Many 
studies on cancer have demonstrated increased 
COX-2 expression both in pre-cancer lesion and 
invasive cancer. Increased COX-2 expression 
and increased production of eicosanoids such as 
PGE2 will activate various inflammatory factors 
and growth factors, which will bring bad effects 
on treatment response.6,7
Modern eating habits nowadays together with 
increased industrial techniques for production 
of vegetable oils and animal fats have caused 
high ω-6 FA intake and deficiency of ω-3 FA 
intake. The ratio of ω-6 : ω-3 FA intake now 
in western countries is about 10-25 : 1.8-10 The 
food sources of ω-6 FA are vegetable oils such 
as corn oil, safflower, soybean oils and animal 
meats. Most of ω-3 fatty acids are found in 
fish oils in the form of EPA and DHA; while 
α-linolenic acid (ALA) is found in vegetable 
oils such as canola, flaxseed, linseed soybean 
oil and green vegetables.9,10 Daily requirements 
of ω-3 fatty acid for patients with cancer has not 
been confirmed, however, the recommendation 
is about 1.6-1.1 g for a healthy adult.11 Based on 
clinical trials, we know that in order to against 
cancer growth, an intake with ratio of ω-6 : ω-3 
fatty acid as much as 1 : 1 or 2 : 1 is necessary.3,4
Our study was aimed to investigate whether a 
dietary supplementation enriched with high-ω-3 
fatty acid intake together with radiation therapy 
can reduce the inflammatory status in patients 
with advanced cervical cancer, therefore, it is 
expected that it may enhance tumor response to 
radiation therapy.
METHODS
A randomized double-blind clinical trial 
was conducted in patients with advanced 
cervical cancer of stage II-IIIB squamous cell 
carcinoma and who had only received radiation 
therapy at Department of Radiotherapy, Cipto 
Mangunkusumo Hospital. Data collection had 
been performed since April 2013 until the 
required sample size had been completed. The 
inclusion criteria were: patients aged ≥18 years, 
with Karnofsky Index of ≥60%, with BMI of 
≥16 kg/m2, who could and were willing to drink 
milk and willing to sign the informed consent 
form. The exclusion criteria were those with 
liver dysfunction (SGOT >38 U/L, SGPT >41 
U/L), renal dysfunction (ureum serum level >50 
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mg/dL, creatinine serum level >1.4 mg/dL), 
metabolic disorder (random blood glucose level 
≥200 mg/dL) and fat malabsorption. The samples 
were collected using consecutive sampling and 
randomization was performed using sealed 
envelopes. The subjects were randomized 
according to the number on the envelopes into 
2 groups, i.e. the treatment and control groups. 
Dietary supplementation was provided in the 
form of milk with A and B labeling. The products 
were isocaloric and isoprotein, but one of them 
was enriched with PUFA. Products containing 
PUFA were concealed by the manufacturer. 
The laboratory work-up measuring serum 
PGE2 level was performed before and after a 
complete treatment of external radiation. The 
measurement was done using ELISA method. 
The subjects were considered drop out when 
they did not follow study protocol or if there was 
a delay of radiation treatment in 7 consecutive 
days or if they took the dietary supplementation 
of <80%. The analysis of dietary intake during 
the treatment was conducted using food-recall 
and food-record method. In order to control the 
compliance of the subjects during the study, 
the milk supplementation should be taken 3 
times, i.e. before and after radiation treatment, 
which were taken at the site of the study, and 
the third was taken at home (the milk package 
should be returned and the subjects should fill 
in the diary of dietary supplementation). The 
study protocol has been approved by Research 
Ethics Committee of the Faculty of Medicine, 
Universitas Indonesia - Cipto Mangunkusumo 
Hospital.
Statistical Analysis
Data were edited, coded and processed using 
a computer program of Statistical Program for 
Social Science (SPSS) version 11.5. Univariate 
and bivariate analysis were performed. Normality 
of data distribution was tested using Saphiro-Wilk 
test. If the data distribution was normal (p>0.05), 
we used mean value and standard deviation. 
If the distribution was not normal (p<0.05), 
we used median and range. In the analysis, the 
difference of PGE2 level between the treatment 
group and control group was evaluated; if the data 
of the treatment and control group had normal 
distribution, unpaired t-test was utilized; while 
if one of or both data had abnormal distribution, 
we used Mann-Whitney test.
RESULTS
The study lasted for 12 months, i.e. between 
April 2013 and April 2014. Based on the inclusion 
and exclusion criteria, there were 45 patients with 
advanced cervical cancer, who was at stage IIB 
– IIIB and had received radiation treatment. At 
the end of study, there were 31 subjects who had 
completed the study protocol; while 14 subjects 
were considered drop out. There were 16 subjects 
who had received product A in the treatment 
group; while 15 subjects who had received 
product B were included in the control group.
The distribution of subjects before treatment 
(Table 1) did not show significant difference 
between the treatment and control group. Most 
subjects aged ≥45 years. The nutritional status 
of study subjects, which was based on BMI 
according to WHO classification for Asia Pacific 
population, was still in normal category (normal 
BMI: 18.5-22.9 kg/m2); some of them were even 
overweight. Based on the stage of illness, there 
were 21 subjects (68%) who were at the stage 
of IIIB.
Table 1. Subject distribution based on age, nutritional 









 - <45 years (n) 7 4 0.320a
 - ≥45 years (n) 9 11
BMI 
 - Underweight (n) 2 -
 - Normoweight (n) 7 8 1.000a
 - Overweight (n) 7 7
Stage according to 
FIGO classification
 - IIB (n) 6 4 0.704a
 - IIIB (n) 10 11
a Uji Chi Square
The dietary intake of study subjects during 
their external radiation treatment was evaluated 
using the diary which was written by the patients 
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themselves. We found a significant difference in 
terms of ω-3 FA intake and the intake ratio of 
ω-6 : ω-3 FA, i.e. the treatment group had higher 
ω-3 FA intake compared to the control group.
We found reduced PGE2 level by 8.9% in 
the treatment group; while the control group had 
increased level by 28.1%; however, there was 
statistically no significant difference (Table 3). A 
value of NNT (number needed to treat) of 11.11, 
which means that we need to treat 11 patients 
with interventional product/PUFA in order to 
reduce the PGE2 level.
sources. There are two types of essential fatty 
acids (FA), i.e. ω-6 and ω-3 FA. In daily intake, 
the major food sources for ω-6 FA are in the form 
of linoleic acid (LA) and arachidonic acid; while 
the ω-3 FA is obtained in the form of α-linolenic 
acid (ALA), EPA and DHA. Those fatty acids 
are structural components of phospholipid in 
membrane cell, which have important function 
to maintain the membrane fluidity, signaling and 
interaction between cells. Moreover, the fatty 
acids are precursors for producing eicosanoids, 
i.e. prostaglandin (PG), thromboxane (TX) dan 
leukotriene (LT) with the help of Cyclooxygenase 
(COX) and Lipoxygenase (LOX) enzymes.12 
Eicosanoids are hormone-like substances 
which are originated from oxygenation of 
essential fatty acids containing 20 carbon 
chains, i.e. the AA (ω-6 FA) and EPA (ω-3 FA). 
Eicosanoids also have roles in inflammatory 
response, controlling immune response, platelet 
aggregation, smooth muscle contraction, cell 
growth and differentiation. A balanced ratio 
of ω-6 and ω-3 intake of 1-4 : 1 is essential to 
maintain homeostasis as well as normal growth 
and development.10,12
In addition to reducing PGE2 through its 
competition with AA as the substrate of COX 
enzyme, ω-3 FA also can inhibit signals for 
PGE2 receptor on cell membrane; thus, it reduces 
inflammatory signal. An in vivo study conducted 
by Ruan and So13 provided evidences that fish 
oil (particularly DHA) can significantly inhibit 
PGE2 signal by inhibiting the binding of PGE2 
with EP1 receptor and it is also assumed that it 
is also applied for other PGE2 receptors, i.e. the 
EP2, EP3 and EP4.
Theoretically, reduced PGE2 level will lower 
the survival of cancer cells; while in contrast, 
increased PGE2 will also increase the survival. 
Prostaglandin E2 and its receptors have important 
role in cancer development, proliferation, 
apoptosis, angiogenesis, immunosuppression, 
tumor invasion and metastases.6 The magnitude of 
prostaglandin effect depends on its concentration 
in the body. The effect of ω-6 : ω-3 level ratio on 
the composition of fatty acids in the plasma and 
prostanoid synthesis has been studied by Amira 
et al.14 in an in vivo study, which demonstrated 
that a dietary intake with fatty acid ratio of ω-6: 
Table 2. Dietary intake of ω-6 and ω-3 FA and Intake 














Dietary intake of 
ω-3 FA (g)
2.72 ± 0.31 0.51 ± 0.16 <0.001b
Intake ratio of 





a Mann Whitney Test; b Independent T-Test
ω-3 FA = ω-3 fatty acid; ω-6 FA = ω-6 fatty acid

































a  Mann Whitney Test; b Unpaired T-test
PGE2 = Prostaglandin E2
DISCUSSION
Polyunsaturated fatty acid (PUFA) is an 
essential fatty acid, which cannot be synthesized 
by the body and must be obtained from food 
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ω-3 = 1 : 1 may result in a higher ω-3 FA level 
(p<0.05), a lower FA ratio of ω-6 : n-e (p<0.05) 
and lower level of AA (p<0.05) compared to the 
ratio of 6:1 or 30:1; moreover, they also found 
significant increase of plasma PGE2 level in the 
group with a ratio of 30 : 1.
It indicates that the ratio of FA intake ω-6 : 
ω-3 affects the profile of plasma fatty acid, as 
well as the development of PGF2α and PGE2. 
Kobayashi at al.8 and Calviello et al.15 also 
demonstrated that a dietary intake with FA ratio 
ω-6 : ω-3 = 1:1 might reduce the expression of 
COX-2 and PGE2 level. The reduced PGE2 level 
was then followed by reduced proliferation and 
increased apoptosis of cancer cells which were 
impregnated in rats.
Our study showed that high-PUFA dietary 
supplementation with ω-6 : ω-3 FA ratio of 
1.27: 1 during treatment using external radiation 
can reduce PGE2 level as much as 8.9 ± 42.9% 
in the treatment group; while in the control 
group which did not receive PUFA, there was 
an increased PGE2 of 28.1 ± 80.2% although 
statistically the difference was not significant.
CONCLUSION
Dietary supplementation of ω-3 FA in 
patients with advanced cervical cancer may 
help to reduce the inflammation. It is suggested 
that patients with cancer should increase 
their high ω-3 FA dietary intake or having a 
dietary supplementation enriched with ω-3 FA; 
therefore, the reduced inflammatory status may 
enhance tumor response to radiation therapy. 
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